Published in Arthritis Rheum on August 01, 2004
Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther (2009) 2.05
The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther (2008) 1.56
Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort. Ann Rheum Dis (2006) 1.47
Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis (2007) 1.43
Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis (2005) 1.37
Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? Ann Rheum Dis (2005) 1.30
Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities. Arthritis Res Ther (2011) 1.22
Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. Arthritis Rheum (2009) 1.21
Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 1.18
Osteoporosis in ankylosing spondylitis - prevalence, risk factors and methods of assessment. Arthritis Res Ther (2012) 1.13
Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-derived collagen species: a cross-sectional study. Rheumatol Int (2011) 1.00
Determinants of hyperkyphosis in patients with ankylosing spondylitis. Ann Rheum Dis (2005) 0.99
The genetic basis of ankylosing spondylitis: new insights into disease pathogenesis. Appl Clin Genet (2014) 0.96
Disease modification in ankylosing spondylitis. Nat Rev Rheumatol (2010) 0.96
Update on the treatment of ankylosing spondylitis. Ther Clin Risk Manag (2007) 0.93
Quantitative measurement of syndesmophyte volume and height in ankylosing spondylitis using CT. Ann Rheum Dis (2013) 0.92
Gender characterization in a large series of Brazilian patients with spondyloarthritis. Clin Rheumatol (2011) 0.90
Scoring of radiographic progression in randomised clinical trials in ankylosing spondylitis: a preference for paired reading order. Ann Rheum Dis (2004) 0.89
Imaging of the sacroiliac joint involvement in seronegative spondylarthropathies. Clin Rheumatol (2009) 0.88
Higher bone turnover is related to spinal radiographic damage and low bone mineral density in ankylosing spondylitis patients with active disease: a cross-sectional analysis. PLoS One (2014) 0.86
Progress in spondylarthritis. Spondyloarthritis: lessons from imaging. Arthritis Res Ther (2009) 0.85
What do biomarkers tell us about the pathogenesis of ankylosing spondylitis? Arthritis Res Ther (2009) 0.85
[Outcome parameters in ankylosing spondylitis]. Z Rheumatol (2006) 0.85
The effect of smoking on clinical and radiographic variables, and acute phase reactants in patients with ankylosing spondylitis. Rheumatol Int (2015) 0.84
[Imaging in ankylosing spondylitis]. Z Rheumatol (2007) 0.82
MRI and X-ray in axial spondyloarthritis: the relationship between inflammatory and structural changes. Arthritis Res Ther (2012) 0.81
Developments in the scientific and clinical understanding of the spondyloarthritides. Arthritis Res Ther (2009) 0.81
Ankylosing spondylitis: patterns of radiographic involvement--a re-examination of accepted principles in a cohort of 769 patients. Radiology (2010) 0.81
Outcomes in ankylosing spondylitis: what makes the assessment of treatment effects in ankylosing spondylitis different? Ann Rheum Dis (2006) 0.81
Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)? Arthritis Res Ther (2013) 0.80
Comparison of the Bath Ankylosing Spondylitis Radiology Index and the modified Stoke Ankylosing Spondylitis Spine Score in Turkish patients with ankylosing spondylitis. Clin Rheumatol (2009) 0.80
Clinimetric properties of the ASAS health index in a cohort of Italian patients with axial spondyloarthritis. Health Qual Life Outcomes (2016) 0.79
Cartilage collagen type II seromarker patterns in axial spondyloarthritis and psoriatic arthritis: associations with disease activity, smoking and HLA-B27. Rheumatol Int (2015) 0.79
Value of multidetector computed tomography for the radiologic grading of sacroiliitis in ankylosing spondylitis. Rheumatol Int (2012) 0.79
Serum leptin levels are associated with the presence of syndesmophytes in male patients with ankylosing spondylitis. Clin Rheumatol (2012) 0.78
Measurement and treatment of radiographic progression in ankylosing spondylitis: lessons learned from observational studies and clinical trials. Curr Opin Rheumatol (2014) 0.78
Dynamics of syndesmophyte growth in AS as measured by quantitative CT: heterogeneity within and among vertebral disc spaces. Rheumatology (Oxford) (2014) 0.78
Spinal radiographic progression in patients with ankylosing spondylitis treated with TNF-α blocking therapy: a prospective longitudinal observational cohort study. PLoS One (2015) 0.78
[Ankylosing spondylitis--current state of imaging including scoring methods]. Z Rheumatol (2006) 0.78
Spondyloarthritides: evolving therapies. Arthritis Res Ther (2010) 0.77
Updating the OMERACT filter: implications for imaging and soluble biomarkers. J Rheumatol (2014) 0.77
Construct validity of clinical spinal mobility tests in ankylosing spondylitis: a systematic review and meta-analysis. Clin Rheumatol (2015) 0.76
Infliximab in the treatment of ankylosing spondylitis. Biologics (2007) 0.76
Imaging in ankylosing spondylitis. Ther Adv Musculoskelet Dis (2012) 0.76
Tools for monitoring spondyloarthritis in clinical practice. Nat Rev Rheumatol (2009) 0.75
Bone morphogenetic protein 6 polymorphisms are associated with radiographic progression in ankylosing spondylitis. PLoS One (2014) 0.75
Predictive factors of radiographic progression in ankylosing spondylitis. Korean J Intern Med (2015) 0.75
Severe bone marrow edema on sacroiliac joint MRI increases the risk of low BMD in patients with axial spondyloarthritis. Sci Rep (2016) 0.75
The FAt Spondyloarthritis Spine Score (FASSS): development and validation of a new scoring method for the evaluation of fat lesions in the spine of patients with axial spondyloarthritis. Arthritis Res Ther (2013) 0.75
Spatial distribution of syndesmophytes along the vertebral rim in ankylosing spondylitis: preferential involvement of the posterolateral rim. Ann Rheum Dis (2016) 0.75
Incorporating assessment of the cervical facet joints in the modified Stoke ankylosing spondylitis spine score is of additional value in the evaluation of spinal radiographic outcome in ankylosing spondylitis. Arthritis Res Ther (2017) 0.75
Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort. Medicine (Baltimore) (2016) 0.75
Alterations of bone mineral density, bone microarchitecture and strength in patients with ankylosing spondylitis: a cross-sectional study using high-resolution peripheral quantitative computerized tomography and finite element analysis. Arthritis Res Ther (2015) 0.75
Mechanism of New Bone Formation in Axial Spondyloarthritis. Curr Rheumatol Rep (2017) 0.75
Comparison of radiological indices (SASSS, M-SASSS, BASRI-s, BASRI-t) in patients with ankylosing spondylitis. Rheumatol Int (2011) 0.75
Loss of anterior concavity of the first sacrum can predict spinal involvement in ankylosing spondylitis. Rheumatol Int (2015) 0.75
Digital tomosynthesis as a new diagnostic tool for evaluation of spine damage in patients with ankylosing spondylitis. Rheumatol Int (2016) 0.75
[Early therapy of axial spondyloarthritis and relevance of radiological progression]. Z Rheumatol (2012) 0.75
[Ankylosing spondylitis. Target treatment criteria]. Z Rheumatol (2009) 0.75
[Outcome parameters for use in psoriatic arthritis]. Z Rheumatol (2006) 0.75
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum (2010) 18.82
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis (2010) 12.12
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) (2012) 12.07
Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis (2010) 10.97
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis (2013) 10.92
Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum (2006) 10.39
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis (2010) 10.03
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum (2006) 8.78
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med (2005) 6.37
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum (2011) 6.28
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum (2004) 6.22
COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum (2002) 5.57
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med (2003) 4.67
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis (2011) 4.15
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2005) 3.64
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2006) 3.51
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum (2003) 3.47
Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum (2005) 3.31
Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: a cross-sectional study. Arthritis Rheum (2003) 3.09
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis (2012) 3.00
The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum (2004) 2.99
Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int (2002) 2.95
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis (2010) 2.91
Development of classification and response criteria for rheumatic diseases. Arthritis Rheum (2006) 2.88
Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum (2002) 2.66
2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis (2011) 2.61
Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum (2008) 2.41
Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum (2002) 2.35
Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria. J Rheumatol (2003) 2.33
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum (2007) 2.31
The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. Arthritis Rheumatol (2014) 2.14
EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis (2013) 2.05
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther (2005) 1.96
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum (2010) 1.94
Which variables best predict change in rheumatoid arthritis therapy in daily clinical practice? J Rheumatol (2006) 1.92
Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum (2002) 1.86
The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing. Arthritis Rheum (2003) 1.84
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med (2015) 1.83
B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum (2011) 1.83
Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine (2006) 1.77
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis (2013) 1.74
Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol (2006) 1.71
Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol (2005) 1.70
Cross-sectional association of 10 molecular markers of bone, cartilage, and synovium with disease activity and radiological joint damage in patients with hip osteoarthritis: the ECHODIAH cohort. J Rheumatol (2005) 1.69
Clinical vertebral fractures in patients with ankylosing spondylitis. J Rheumatol (2004) 1.68
Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. Arthritis Rheum (2013) 1.67
Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol (2003) 1.65
Refractory inflammatory heel pain in spondylarthropathy: a significant response to infliximab documented by ultrasound. Arthritis Rheum (2002) 1.65
Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. J Rheumatol (2005) 1.62
Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev (2014) 1.60
Comparative study of MRI and power Doppler ultrasonography of the heel in patients with spondyloarthritis with and without heel pain and in controls. Ann Rheum Dis (2011) 1.59
Effect of a collective educational program for patients with rheumatoid arthritis: a prospective 12-month randomized controlled trial. J Rheumatol (2007) 1.57
Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab. J Rheumatol (2005) 1.55
Reliability of ultrasonography to detect synovitis in rheumatoid arthritis: a systematic literature review of 35 studies (1,415 patients). Arthritis Care Res (Hoboken) (2010) 1.54
Images in clinical medicine. A medical mystery--arthritis. N Engl J Med (2006) 1.54
Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol (2009) 1.54
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. Ann Rheum Dis (2010) 1.53
Diagnostic performance and predictive value of rheumatoid factor, anti-citrullinated peptide antibodies, and the HLA shared epitope for diagnosis of rheumatoid arthritis. Clin Chem (2004) 1.53
Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. Ann Rheum Dis (2011) 1.53
Health assessment questionnaire score is the best predictor of 5-year quality of life in early rheumatoid arthritis. J Rheumatol (2006) 1.53
Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology. J Rheumatol (2012) 1.52
Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford) (2009) 1.51
Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum (2007) 1.49
Treatment of osteoarthritis with continuous versus intermittent celecoxib. J Rheumatol (2011) 1.49
Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. Ann Rheum Dis (2009) 1.48
Is screening for hepatitis B and hepatitis C useful in patients with recent-onset polyarthritis? The ESPOIR cohort study. J Rheumatol (2009) 1.47
Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum (2005) 1.46
Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis (2010) 1.44
Combinatorial control of Th17 and Th1 cell functions by genetic variations in genes associated with the interleukin-23 signaling pathway in spondyloarthritis. Arthritis Rheum (2013) 1.44
The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. Joint Bone Spine (2007) 1.44
Association between serum uric acid, aortic, carotid and femoral stiffness among adults aged 40-75 years without and with type 2 diabetes mellitus: The Maastricht Study. J Hypertens (2015) 1.42
Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort. J Rheumatol (2013) 1.42
Radiological scoring methods in ankylosing spondylitis. Reliability and change over 1 and 2 years. J Rheumatol (2004) 1.42
Aspects of validity of the self-administered comorbidity questionnaire in patients with ankylosing spondylitis. Rheumatology (Oxford) (2014) 1.40
Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Arthritis Rheum (2010) 1.40
ICF Core Sets for low back pain. J Rehabil Med (2004) 1.40
Can remission in rheumatoid arthritis be assessed without laboratory tests or a formal joint count? possible remission criteria based on a self-report RAPID3 score and careful joint examination in the ESPOIR cohort. J Rheumatol (2013) 1.39
Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis (2009) 1.39
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis (2012) 1.33
Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. J Rheumatol (2007) 1.33
Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology (Oxford) (2012) 1.31
Reporting of adherence to medication in recent randomized controlled trials of 6 chronic diseases: a systematic literature review. Am J Med Sci (2007) 1.31
Smoking and overweight determine the likelihood of developing rheumatoid arthritis. Ann Rheum Dis (2012) 1.30
Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. Ann Rheum Dis (2012) 1.30
ASsessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis Rheum (2005) 1.28
Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis. Arthritis Res Ther (2006) 1.27
Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther (2011) 1.24
Pigmented villonodular synovitis: a retrospective single-center study of 122 cases and review of the literature. Semin Arthritis Rheum (2010) 1.24
Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol (2007) 1.23